Episurf Medical
Prospective Episealer® Talus clinical study fully recruited
Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective clinical study on the Episealer Talus® implant, led by Prof. Stefano Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca and Prof. Niek van Dijk.
The study will follow 20 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical's CE marked implant technology, intended for the treatment of ankle lesions.
"Our technology for ankle lesions is getting more and more attention internationally and we are very pleased that this study is fully recruited. The study started under difficult conditions during the pandemic, but the recruitment has now been concluded in a very efficient way. We are looking forward to the results, and it is, as always, an honour to work with the prestigious Rizzoli Orthopaedic Institute in Bologna," says Pål Ryfors, CEO Episurf Medical.
| Datum | 2023-09-13, kl 10:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!